Loading…
Employees: 3,401
Size Nephrocare Health Services (NEPHROPLUS.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $639M, the 752nd largest of 1,058 India companies the cockpit tracks. Shares closed at ₹601.75 on 6 Nov 2026.
Performance Over six months the shares gained 10.4%, against -2.1% for the median peer and 0.0% for the India market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 32.9% over the last twelve months (peer median +6.0%); the operating margin is 13.8% (peer median 7.6%).
Valuation It trades at 41.9× forward earnings against a peer median of 17.9× (2nd most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.0 points below its cost of capital (12.5% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ₹9.97B | ₹7.50B | ₹5.57B | ₹4.37B |
| Revenue growth | — | +33% | +35% | +27% | — |
| Gross profit | n/a | ₹2.88B | ₹1.73B | ₹1.06B | ₹537M |
| EBITDA | n/a | ₹2.27B | ₹1.63B | ₹945M | ₹486M |
| Net income | n/a | ₹768M | ₹671M | ₹351M | -₹118M |
| Free cash flow | n/a | ₹1.03B | ₹298M | -₹141M | -₹699M |
| Capital expenditure | n/a | ₹1.19B | ₹1.01B | ₹800M | ₹737M |
| Total debt | ₹1.49B | ₹797M | ₹2.58B | ₹2.68B | ₹2.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEPHROPLUS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.2% | -3.2% | 9th lowest of 21 |
| 6-month return | +10.4% | -2.1% | 4th highest of 20 |
| Distance from 52-week high | -23.0% | -28.8% | 9th highest of 21 |
| Revenue growth (TTM) | +32.9% | +6.0% | 4th highest of 21 |
| Operating margin | 13.8% | 7.6% | 4th highest of 21 |
| Forward P/E | 41.9× | 17.9× | 2nd most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 35.7% | 8.5% | most demanding of 17 |
| Growth delivered (Del g) | +31.6% | +11.5% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | +4.0 pp | -9.1 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | -1.0 pp | -2.2 pp | 10th highest of 20 |
| EV / EBITDA | 25.3× | 8.4× | 2nd most expensive of 14 |
| Net debt / EBITDA | -1.3× | 1.7× | 5th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |
| Jeena Sikho Lifecare JSLL.NS | India | $424M | -56% | +162% | 36% | 13.9× | 8.1% | +42.6% |
| Australian Clinical Labs ACL.AX | Australia | $419M | +74% | -1% | 8% | 17.3× | 3.9% | +2.6% |
| ADICON 9860.HK | Hong Kong | $408M | +9% | +1% | 4% | 25.5× | 12.0% | -1.5% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Tellgen 300642.SZ | China | $387M | -3% | +5% | 8% | n/a | 22.4% | -5.8% |
| M1 Kliniken M12.DE | Germany | $376M | +3% | -28% | 13% | 18.5× | -5.5% | +17.9% |